FDA Approves Empaveli for Rare Kidney Diseases

Approval is first treatment for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis
vial
Adobe Stock
Published on
Updated on
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com